Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November

About this update from Artiva Biotherapeutics, Inc.

[{"type":"image","alt":"Artiva Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Artiva Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":163,"url":"https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qlnfoD..J1RiP0FeWYqi_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43","width":300,"height":163}},"lazy":false},{"type":"text","content":"SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) --  Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate at the following investor conferences:","length":360,"tagName":"p"},{"type":"text","content":"TD Cowen's Immunology & Inflammation Summit (Virtual) - fireside chat on Wednesday, November 12, 2025, at 11:30 a.m. ET","length":127,"tagName":"p"},{"type":"text","content":"2025 Jefferies Global Healthcare Conference in London - fireside chat on Tuesday, November 18, 2025, at 12:00 p.m. GMT","length":118,"tagName":"p"},{"type":"text","content":"The Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conferences.","length":146,"tagName":"p"},{"type":"text","content":"Investors and the general public are invited to listen to a live webcast of each of these presentations through the "Investors" section on Artivabio.com. A webcast replay will be made available following each event for 90 days.","length":242,"tagName":"p"},{"type":"text","content":"About Artiva Biotherapeutics","length":28,"tagName":"p"},{"type":"text","content":"Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. Al...

More updates from Artiva Biotherapeutics, Inc.